Guardant Health, Inc.
Gene mutations and copy number alterations of EGFR, KRAS and MET

Abstract:

Sequence variants and copy number variations in the EGFR, KRAS and MET genes are biomarkers for resistance to anti-EGFR therapies for cancer. This disclosure provides methods of detecting these biomarkers and using them in the diagnosis and treatment of cancer.